Overview

Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction

Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)
Phase:
Phase 2
Details
Lead Sponsor:
AxeroVision, Inc.